Paradigm Capital Management Inc. NY Makes New Investment in QuidelOrtho Corporation $QDEL

Paradigm Capital Management Inc. NY purchased a new position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,521,700 shares of the company’s stock, valued at approximately $44,168,000. QuidelOrtho accounts for approximately 1.2% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 19th biggest position. Paradigm Capital Management Inc. NY owned about 3.68% of QuidelOrtho at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in QDEL. Quantbot Technologies LP acquired a new stake in shares of QuidelOrtho in the second quarter valued at about $419,000. Allworth Financial LP acquired a new position in QuidelOrtho during the second quarter worth about $56,000. Tejara Capital Ltd acquired a new position in QuidelOrtho during the second quarter worth about $2,275,000. BlackRock Inc. purchased a new position in QuidelOrtho in the second quarter valued at about $196,212,000. Finally, Deutsche Bank AG purchased a new position in QuidelOrtho in the second quarter valued at about $1,616,000. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Down 1.7%

Shares of NASDAQ QDEL opened at $14.49 on Tuesday. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58. The company has a market capitalization of $993.65 million, a PE ratio of -0.94 and a beta of 0.68. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm’s 50-day moving average is $15.82 and its two-hundred day moving average is $16.34.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same period in the prior year, the business earned $0.12 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities analysts anticipate that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on QDEL. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Zacks Research cut QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. boosted their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research report on Wednesday, July 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $13.62.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.